[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"esophageal-varices\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:esophageal-varices":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,55,85,108,127,151,181,202,225,247,277,297],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100639849","underdilated-vcx-tips-versus-evl-plus-nsbb-for-secondary-prophylaxis-of-variceal-bleeding-in-cirrhosis-100639849",false,"NCT07587671","Underdilated VCX-TIPS Versus EVL Plus NSBB for Secondary Prophylaxis of Variceal Bleeding in Cirrhosis","Underdilated VIATORR Controlled Expansion Transjugular Intrahepatic Portosystemic Shunt Versus Endoscopic Variceal Ligation Plus Nonselective Beta-Blockers for Secondary Prophylaxis of Variceal Bleeding in Patients With Cirrhosis: A Multicenter, Open-Label, Randomized Controlled Trial","U-TIPS","Inclusion Criteria:\n\n* Age 18 to 75 years, regardless of sex.\n* Diagnosis of liver cirrhosis based on previous histology, imaging, laboratory tests, and\u002For clinical manifestations.\n* Hospitalization for acute upper gastrointestinal bleeding, with endoscopic confirmation that the bleeding is related to esophageal varices or type 1 gastroesophageal varices.\n* Successful control of acute bleeding after standard acute-phase treatment, with stable vital signs and entry into the secondary prophylaxis phase.\n* Child-Pugh score of 5 to 13.\n* The investigator judges that both underdilated VCX-TIPS and EVL plus NSBB are clinically feasible and that randomization is appropriate.\n* The participant or legally authorized representative understands the study procedures and voluntarily signs written informed consent.\n\nExclusion Criteria:\n\n* Hemodynamic instability, persistent active bleeding, or need for immediate rescue TIPS, surgical hemostasis, or interventional radiologic hemostasis.\n* A strong current indication for early or pre-emptive TIPS that makes randomization to EVL plus NSBB clinically inappropriate.\n* Child-Pugh score greater than 13.\n* Previous TIPS, surgical portosystemic shunt, BRTO, CARTO, PARTO, or other procedures that substantially alter portosystemic blood flow.\n* Isolated gastric varices, type 2 gastroesophageal varices, ectopic varices, or a bleeding source other than esophageal varices or type 1 gastroesophageal varices.\n* Non-cirrhotic portal hypertension.\n* Cavernous transformation of the portal vein or portal venous thrombosis that makes standardized TIPS technically infeasible.\n* Previous recurrent or refractory overt hepatic encephalopathy, or a history of West Haven grade II to IV overt hepatic encephalopathy unrelated to gastrointestinal bleeding.\n* Severe heart failure, severe pulmonary hypertension, severe tricuspid regurgitation, right heart failure, or other contraindications to TIPS.\n* Uncontrolled severe infection, sepsis, or multiple organ failure.\n* Hepatocellular carcinoma beyond the Milan criteria or other advanced malignancy.\n* Severe renal insufficiency requiring long-term renal replacement therapy.\n* Pregnancy or breastfeeding.\n* Absolute contraindication to EVL, NSBB, or TIPS.\n* Any condition that, in the investigator's judgment, makes the participant unsuitable for the study or unable to complete follow-up.","ALL","18 Years","75 Years",{"count":21,"type":22},240,"ESTIMATED","INTERVENTIONAL",[25],"NA","Variceal bleeding is a major complication of portal hypertension in patients with cirrhosis and is associated with substantial risks of rebleeding and death. Current guidelines recommend endoscopic variceal ligation combined with nonselective beta-blockers as standard secondary prophylaxis for esophageal variceal bleeding and type 1 gastroesophageal variceal bleeding. Transjugular intrahepatic portosystemic shunt can markedly reduce portal pressure and prevent recurrent variceal bleeding, but its broader use in secondary prophylaxis is limited by the risk of post-TIPS hepatic encephalopathy and liver function deterioration.\n\nThe VIATORR Controlled Expansion stent is designed to allow controlled expansion between 8 and 10 mm. However, even 8-mm TIPS may still be associated with a substantial risk of overt hepatic encephalopathy. This trial evaluates an underdilated VCX-TIPS strategy, in which a commercially available 8-10 mm VIATORR Controlled Expansion stent is initially dilated only with a 6-mm balloon, aiming to achieve sufficient portal decompression while reducing the risk of excessive shunting.\n\nThis is a prospective, multicenter, open-label, parallel-group, randomized superiority trial. Eligible patients with cirrhosis who have recovered from acute esophageal variceal bleeding or type 1 gastroesophageal variceal bleeding and have entered the secondary prophylaxis phase will be randomly assigned in a 1:1 ratio to receive either underdilated VCX-TIPS or endoscopic variceal ligation plus nonselective beta-blockers. The primary outcome is the composite of all-cause death or clinically significant upper gastrointestinal rebleeding within 1 year after randomization.",[28,29,30,31,32],"Liver Cirrhosis","Portal Hypertension","Gastroesophageal Varices Bleeding","Esophageal Varices","Hepatic Encephalopathy",[34,35,36,37,38,39,40,41],"Cirrhosis","Portal hypertension","Esophageal variceal bleeding","Secondary prophylaxis","Transjugular intrahepatic portosystemic shunt","Underdilation","Endoscopic variceal ligation","Hepatic encephalopathy","NOT_YET_RECRUITING","2026-05-07",{"date":45,"type":46},"2026-05-14","ACTUAL",{"date":48,"type":22},"2026-08-01",{"date":50,"type":22},"2030-07-30",{"name":52,"class":53},"West China Hospital","OTHER",3,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":4,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":65,"conditions":66,"keywords":71,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":4},"100636914","ultrasound-prediction-of-esophageal-variceal-bleeding-risk-100636914","NCT07571876","Ultrasound Prediction of Esophageal Variceal Bleeding Risk","Splenic Size and Portal Vein Diameter on Ultrasound in Predicting Esophageal Variceal Bleeding Risk","Inclusion Criteria:\n\n* Adult patients (age ≥18 years) with chronic liver disease and clinical\u002Flaboratory\u002Fradiological evidence of liver cirrhosis\n* Both compensated and decompensated cirrhosis (Child-Pugh classes A, B, and C)\n* Patients scheduled for upper gastrointestinal endoscopy\n* Patients who provide informed consent\n\nExclusion Criteria:\n\n* Previous history of endoscopic variceal band ligation or sclerotherapy\n* Prior surgical portosystemic shunt procedures or transjugular intrahepatic portosystemic shunt (TIPS)\n* Hepatocellular carcinoma with portal vein thrombosis\n* Previous splenectomy\n* Patients receiving beta-blockers for variceal bleeding prophylaxis\n* Poor quality ultrasound images due to obesity or ascites\n* Refusal to participate in the study",{"count":63,"type":22},165,"OBSERVATIONAL","This prospective observational study aims to evaluate the accuracy of using routine abdominal ultrasound to predict the risk of esophageal variceal bleeding in adult patients with liver cirrhosis. Esophageal variceal bleeding is a serious complication of chronic liver disease. While upper gastrointestinal endoscopy is the current standard for diagnosing and grading these varices, it is an invasive procedure.\n\nIn this study, researchers will use ultrasound to measure the patient's spleen size and portal vein diameter. These non-invasive measurements will then be compared to the results of a standard upper endoscopy performed within 48 to 72 hours. The goal is to determine if these simple ultrasound measurements can reliably predict the presence, grade, and bleeding risk of esophageal varices, which could potentially reduce the need for routine invasive endoscopic screenings in the future.",[67,68,69,31,28,29,70],"Variceal Bleeding","Ultrasonography","Esophageal Bleeding","Chronic Liver Disease (CLD)",[72,73,74,75],"portal vein diameter","splenic size","ultrasound","esophageal variceal bleeding risk","2026-05-04",{"date":78,"type":46},"2026-05-06",{"date":80,"type":22},"2026-04",{"date":82,"type":22},"2027-05",{"name":84,"class":53},"Assiut University",{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":92,"targetDuration":94,"studyType":64,"phases":4,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":4},"100631595","optimizing-endoscopic-and-interventional-treatment-for-portal-hypertensive-bleeding-100631595","NCT07502729","Optimizing Endoscopic and Interventional Treatment for Portal Hypertensive Bleeding","Improve the Strategies of Endoscopic and Interventional Treatment of Gastroesophageal Hemorrhage in Portal Hypertension","Inclusion Criteria:\n\n* Admitted due to gastrointestinal bleeding and clinically diagnosed with portal hypertension\n* Underwent imaging examinations and gastroscopy within one week after admission\n* Gastroscopy revealed the presence of esophageal and\u002For gastric varices\n* Age over 18 years\n\nExclusion Criteria:\n\n* Previous history of liver transplantation\n* Imaging or gastroscopy findings indicated ulcers or other causes of gastrointestinal bleeding\n* Concurrent severe life-threatening diseases involving the circulatory, hematological, or respiratory systems\n* Difficulty in follow-up, or lack of essential medical history information, imaging data, or other necessary records",{"count":93,"type":22},1066,"12 Months","This study aims to evaluate the impact of high-risk factors-such as elevated portal venous pressure, concurrent large extra-luminal vessels, portal vein thrombosis, and prominent portosystemic shunts-on the efficacy of endoscopic therapy. By comparing with interventional treatment, the goal is to optimize the clinical management protocol for esophageal and gastric varices, enhance the therapeutic outcomes of portal hypertension-related esophageal and gastric varices, and improve patient prognosis.",[29,97,98,31],"Gastroesophageal Varices Hemorrhage","Gastric Varices","2026-03-24",{"date":101,"type":46},"2026-03-31",{"date":103,"type":22},"2026-03-17",{"date":105,"type":22},"2027-12-31",{"name":107,"class":53},"Shanghai Zhongshan Hospital",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":115,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":4},"100628659","non-invasive-predictors-of-esophageal-varices-and-their-correlation-to-upper-endoscopic-findings-100628659","NCT07464522","Non-invasive Predictors of Esophageal Varices and Their Correlation to Upper Endoscopic Findings","Non-invasive Predictors of Esophageal Varices in Pediatric Portal Hypertension and Their Correlation to Upper Endoscopic Findings","Inclusion Criteria:\n\n* Patients aged less than 18 years diagnosed with portal hypertension either due to hepatic or extrahepatic causes\n\nExclusion Criteria:\n\n* Active variceal bleeding at presentation (hemodynamic instability affects platelet\u002Fspleen parameters).\n* Previous history of variceal bleeding or endoscopic intervention (band ligation\u002Fsclerotherapy).\n* Prior surgical portosystemic shunts or Transjugular Intrahepatic Portosystemic Shunt (TIPS).\n* Current use of vasoactive drugs for primary prophylaxis (e.g., Non-selective beta-blockers).\n* Systemic infections or hematological disorders causing independent thrombocytopenia or splenomegaly (to avoid confounding the platelet\u002Fspleen ratio).",{"count":116,"type":22},51,"The goal of this observational study:\n\n* To evaluate the diagnostic accuracy of non-invasive markers in predicting the presence and grading of esophageal varices in children with portal hypertension.\n* To correlate these non-invasive markers with the severity of portal hypertension and the grade of esophageal varices to identify patients at high risk of bleeding.\n* To propose a defined protocol for screening esophageal varices in those children.",[31,29],"2026-03-19",{"date":121,"type":46},"2026-03-23",{"date":123,"type":22},"2026-03-20",{"date":125,"type":22},"2028-05-20",{"name":84,"class":53},{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":134,"targetDuration":136,"studyType":64,"phases":4,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":140,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":150},"100602370","2d-shear-wave-spleen-elastography-in-clinically-significant-portal-hypertension-and-high-risk-varices-100602370","NCT07122622","2D-shear Wave Spleen Elastography in Clinically Significant Portal Hypertension and High-risk Varices","Role of 2D-shear Wave Spleen Elastography in Assessing Clinically Significant Portal Hypertension and High-risk Varices in Patients With Advanced Compensated Chronic Liver Disease.","Inclusion Criteria:\n\n* Age greater than 18 years;\n* SWE-LSM ≥9 kPa and\u002For TE-LSM ≥15 kPa;\n\nExclusion Criteria:\n\n* Presence of transjugular intrahepatic porto-systemic shunt (TIPS);·\n* Surgical absence of the spleen;\n* Grade 3 ascites;\n* History of variceal bleeding;\n* Refusal to participate in the study.",{"count":135,"type":22},450,"2 Years","The primary objective of this study is to evaluate the role of spleen shear wave elastography (SWE-SSM) for ruling in and ruling out clinically significant portal hypertension (CSPH) in patients with compensated advanced chronic liver disease (cACLD) and for ruling in and ruling out high-risk esophageal varices (HRV) in patients with CSPH. Secondary objectives of the study include the investigation of the correlation between SWE-SSM and portal pressure in a subgroup of patients undergoing hepatic venous pressure gradient (HVPG) measurement and between SWE-SSM and transient elastography (TE-SSM).\n\nThe values of SWE-SSM and SWE-LSM will be assessed during the ultrasound examination to which the patient will be subjected according to their care pathway. If inclusion criteria are met and informed consent is obtained, spleen elastography will be carried out (in addition to the routine SWE-LSM planned in clinical practice). Spleen elastography will not alter the standard ultrasound examination but represents a non-invasive diagnostic addition.\n\nThere will be no treatment or experimental intervention that will modify the patient's condition or directly influence their clinical course. The aim is to collect data based on clinical observations without altering the treatment or the natural course of the disease.",[139,31],"Portal Hypertension Related to Cirrhosis","RECRUITING","2025-11-24",{"date":143,"type":46},"2025-11-25",{"date":145,"type":46},"2025-08-20",{"date":147,"type":22},"2027-08-20",{"name":149,"class":53},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",1,{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":161,"conditions":162,"keywords":167,"overallStatus":140,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":150},"100605528","tips-for-complicated-portal-hypertension-related-to-porto-sinusoidal-vascular-disease-100605528","NCT07163689","TIPS for Complicated Portal Hypertension Related to Porto-Sinusoidal Vascular Disease","TIPS for the Management of Complicated Portal Hypertension Related to Porto-Sinusoidal Vascular Disease","TIPS-PSVD","Inclusion Criteria:\n\n* PSVD group :\n* Patient with PSVD according VALDIG criteria\n* TIPS for digestive hemorrhage on portal hypertension\n* TIPS for refractory ascite\n* TIPS for portal vein thrombosis\n* Cirrhosis group with PH : (appaired by age, sexe, type of PH complications)\n* Confirmed cirrhosis with :\n* TIPS for digestive hemorrhage on portal hypertension\n* TIPS for refractory ascite\n* TIPS for portal vein thrombosis\n\nExclusion Criteria:\n\n* no PSVD confirmed diagnosis\n* Budd Chiari syndrome\n* Rendu Osler disease; Heart failure\n* Fontan; Sarcoïdosis\n* Schistosomiase\n* Congenitale liver fibrosis\n* Abernathy syndrome\n* Tumor infiltration by lymphoma\n* Bone graft",{"count":160,"type":22},360,"Porto-sinusoidal Vascular Disease (PSVD) is characterized by a portal hypertension (PH) without cirrhosis. This can induce PH complications, like digestive hemorrhage from esophageal or gastric varices, ascites, or even portal thrombosis. Due to the rarity of MVPS, the treatment of complications of portal hypertension is modeled on the methods used in cirrhotic portal hypertension with non-cardio-selective beta blockers, endoscopic ligations or diuretics in first line therapy, as proposed by the Baveno VII recommendations. In complicated or refractory forms of PH in PSVD, the place of TIPS is also discussed, as in the field of cirrhosis. However, the experience of TIPS in PSVD is limited, reported in case reports and small specifically dedicated series. No predictive factors for survival or recurrence and tolerance were well known. A larger study with control group is needed in order to better know the right time and the right indication for the use of TIPS in complicated PH PSVD-related.\n\nThe study will be retrospective, multicentric involving tertiary university French centers, expert in the management of TIPS. Patients white TIPS-PSVD will be compared with historical patients with TIPS-cirrhose, matched on age, sexe, indication of TIPS. The study will not comprise new intervention, only observational in a real life condition",[163,29,164,165,31,166],"TIPS","Porto-Sinusoidal Vascular Disease","Refractory Ascite","Gastrointestinal Hemorrhage",[163,35,168,169,170,171],"Porto-Sinusoidal Vascular disease","refractory ascite","esophageal varices","gastrointestinal hemorrhage","2025-11-18",{"date":174,"type":46},"2025-11-19",{"date":176,"type":46},"2025-05-16",{"date":178,"type":22},"2025-12",{"name":180,"class":53},"Centre Hospitalier Universitaire, Amiens",{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":90,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":189,"conditions":190,"keywords":191,"overallStatus":140,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":201},"100590675","improve-the-strategies-of-endoscopic-and-interventional-treatment-of-gastroesophageal-hemorrhage-in-portal-hypertension-100590675","NCT06970509","Improve the Strategies of Endoscopic and Interventional Treatment of Gastroesophageal Hemorrhage in Portal Hypertension: Novel Strategies for Diagnosis, Treatment and Prognostic Assessment System of Cirrhotic Portal Hypertension","Inclusion Criteria:\n\n1. Confirmed diagnosis of portal hypertension;\n2. Underwent imaging and endoscopic examination or treatment within one week after admission;\n3. Endoscopy revealed the presence of esophageal and\u002For gastric varices.\n\nExclusion Criteria:\n\n1. CT image slice thickness does not meet the requirements or there are artifacts;\n2. Endoscopy shows no presence of esophageal and\u002For gastric varices;\n3. Presence of severe life-threatening diseases of the circulatory, hematological, or respiratory systems;\n4. Lack of important historical medical information or other relevant data.",{"count":188,"type":22},1450,"Endoscopic esophageal variceal ligation combined with gastric variceal embolization using tissue glue is currently the first-choice method for preventing rebleeding in patients with cirrhosis and portal hypertension. However, the rebleeding rate remains relatively high. Factors such as extra-luminal vascular bundles in the esophagus and stomach walls, and portosystemic shunts significantly affect the therapeutic outcomes. Therefore, there is an urgent need to develop an individualized treatment model for esophagogastric varices based on the anatomical and hemodynamic characteristics of the varices, to stratify patient risks and provide tailored treatment options.\n\nBefore the treatment of esophagogastric varices, the vascular characteristics of esophagogastric varices are assessed based on imaging data such as portal venous CT and ultrasound, as well as clinical information. Risk factors influencing bleeding from esophagogastric varices are explored, and an endoscopic and interventional variceal stratification and treatment model is constructed to provide patients with personalized options for endoscopic or interventional therapy.\n\nDuring the treatment of esophagogastric varices, precise endovascular embolization of the source branch vessels of esophagogastric varices is performed based on hemodynamic models. The safety and efficacy of this treatment strategy are verified through randomized controlled clinical trials.\n\nAfter the treatment of esophagogastric varices, the feasibility of reducing the risk of rebleeding in patients with poor endoscopic outcomes is examined by using drugs that lower portal venous pressure, such as carvedilol or novel oral anticoagulants. Factors influencing recompensation and reversal of portal hypertension are also clarified.",[31,29],[192],"Endoscopic Treatment","2025-05-06",{"date":195,"type":46},"2025-05-14",{"date":197,"type":46},"2025-03-01",{"date":199,"type":22},"2032-12",{"name":107,"class":53},10,{"id":203,"slug":204,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":4,"eligibilityCriteria":208,"healthyVolunteers":209,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":210,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":212,"conditions":213,"keywords":214,"overallStatus":140,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":223,"locationsCount":150},"100585932","fecal-calprotectin-for-prediction-of-esophageal-varices-in-cirrhotic-patients-100585932","NCT06908798","Fecal Calprotectin for Prediction of Esophageal Varices in Cirrhotic Patients","The Accuracy of Fecal Calprotectin in Detecting Esophageal Varices in Egyptian Patients With Liver Cirrhosis","Inclusion Criteria:\n\n* Age ≥18 years\n* Liver cirrhosis\n\nExclusion Criteria:\n\n* Patients aged \\\u003C 18 years.\n* Inflammatory bowel disease.\n* Infectious gastroenteritis.\n* Malignancy.\n* Patients on proton pump inhibitors or NSAID.\n* Patients with spontaneous bacterial peritonitis.\n* Patients with hepatic encephalopathy.\n* Unwilling to participate in our study.",true,{"count":211,"type":22},156,"The goal of this cross-sectional observational study is to evaluate the accuracy of fecal calprotectin versus non-invasive scores in assessing the presence and grading of esophageal varices in Egyptian patients.\n\nResearchers will compare fecal calprotectin levels in cirrhotic patients with and without esophageal varices (EVs) and healthy subjects. researchers will also evaluate the performance of fecal calprotectin, AST to platelet ratio index (APRI) score, fibrosis-4 (FIB-4) score, albumin-bilirubin (ALBI) score, platelet-albumin-bilirubin (PALBI) score, and platelet-spleen diameter ratio (PSR) for predicting esophageal varices.\n\nParticipants will undergo history-taking, clinical examination, laboratory investigations, fecal calprotectin, abdominal ultrasonography, and upper endoscopy. Endoscopic grading of esophageal varices will be done using Paquet's classification. The APRI, FIB-4, ALBI, PALBI, and PSR scores will be calculated. The performance of fecal calprotectin for predicting EVs will be compared versus other non-invasive scores.",[31],[215,170,216],"Fecal calprotectin","liver cirrhosis","2025-03-27",{"date":219,"type":46},"2025-04-03",{"date":221,"type":46},"2024-12-01",{"date":178,"type":22},{"name":224,"class":53},"Tanta University",{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":4,"eligibilityCriteria":231,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":23,"phases":234,"briefSummary":235,"conditions":236,"keywords":237,"overallStatus":140,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":244,"leadSponsor":246,"locationsCount":150},"100583803","cross-section-band-ligation-versus-stepladder-band-ligation-of-esophageal-varices-100583803","NCT06881082","Cross-section Band Ligation Versus Stepladder Band Ligation of Esophageal Varices","Cross-section Band Ligation Versus Stepladder Band Ligation Techniques in Prophylaxis of Esophageal Varices in Cirrhotic Liver Disease. A Randomized Controlled Trial.","Inclusion Criteria:\n\n* Aged \\>18 years.\n* Cirrhotic patients.\n* Endoscopic evidence of medium\u002Flarge-sized esophageal varices.\n\nExclusion Criteria:\n\n* History of variceal bleeding or previous primary prevention of varices.\n* Portal vein thrombosis or previous porto-systemic shunts as TIPS.\n* Patients on drugs affecting portal pressure (beta blockers, nitrates).\n* Advanced cardiovascular disease including acute myocardial infarction, atrio-ventricular block, congestive heart failure, chronic peripheral ischemia, and severe bradycardia.\n* Patients with severe respiratory diseases (COPD, bronchial asthma).\n* Uncontrolled diabetes mellitus.\n* Renal impairment.\n* Hepatocellular carcinoma.\n* Allergy to carvedilol.\n* Pregnancy or lactation.",{"count":233,"type":22},320,[25],"The goal of this randomized controlled trial is to evaluate the cross-section band ligation technique versus the stepladder band ligation technique in esophageal varices prophylaxis.\n\nResearchers will compare cross-section and step ladder band ligation techniques for esophageal varices prophylaxis regarding efficacy, side effects, variceal recurrence, and survival.\n\nParticipants will undergo history-taking, clinical examination, laboratory investigations, and upper endoscopy. Index upper endoscopy will be performed to evaluate the presence, size, and grade of esophageal varices. Patients will be randomly assigned to endoscopic band ligation (EBL) either by cross-section or stepladder techniques every two to four weeks until eradication. After eradication of varices, endoscopy will be repeated after 3-6 months to check for variceal recurrence. For a period of 6 months, all patients in the treatment groups will be followed up every 3 months with clinic visits, including laboratory testing, evaluation of treatment-related side effects, bleeding rates, and mortality from EBL treatment.",[31],[238,239],"Band ligation","esophageal varices prophylaxis","2025-03-11",{"date":242,"type":46},"2025-03-18",{"date":221,"type":46},{"date":245,"type":22},"2025-12-30",{"name":224,"class":53},{"id":248,"slug":249,"hasResults":11,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":253,"eligibilityCriteria":254,"healthyVolunteers":11,"sex":17,"minAge":255,"maxAge":256,"enrollmentInfo":257,"targetDuration":4,"studyType":23,"phases":259,"briefSummary":261,"conditions":262,"keywords":264,"overallStatus":140,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":150},"100561790","phase-4-endoscopic-variceal-ligation-vs-carvedilol-for-the-prevention-of-first-esophageal-variceal-bleeding-in-patients-with-hcc-100561790","NCT06594744","Endoscopic Variceal Ligation vs Carvedilol for the Prevention of First Esophageal Variceal Bleeding in Patients With HCC","A Randomized Controlled Trial of Endoscopic Variceal Ligation Versus Carvedilol for the Prevention of First Esophageal Variceal Bleeding in Patients With Hepatocellular Carcinoma","P-HCC-CVL","Inclusion Criteria:\n\n\\- Patients with HCC and high-risk EVs, confirmed through imaging and clinical data (classified as F2 or F3 EVs according to Beppu et al. classification)\n\nExclusion Criteria:\n\n* Age less than 20 years or greater than 90 years.\n* History of esophageal variceal bleeding.\n* Previous treatment for EVs, including EVL, endoscopic sclerotherapy, transjugular intrahepatic portosystemic shunt (TIPS), or surgical interventions.\n* Use of non-selective β-blockers within two weeks prior to enrollment.\n* Contraindications for non-selective β-blockers, including severe atrioventricular block, chronic obstructive pulmonary disease (COPD), asthma, poorly controlled diabetes, and severe peripheral artery disease.\n* Presence of other end-stage organ diseases, including terminal cancers other than HCC, heart failure, and renal failure.\n* Pregnant women.","20 Years","90 Years",{"count":258,"type":22},120,[260],"PHASE4","The goal of this clinical trial is to evaluate whether endoscopic variceal ligation (EVL) or carvedilol is more effective at preventing the first esophageal variceal bleeding (EVB) in patients with hepatocellular carcinoma (HCC). It will also learn about the safety of EVL and carvedilol in patients with HCC. The main questions it aims to answer are:\n\nWhether EVL or carvedilol is more effective at preventing initial EVB in patients with HCC with high-risk EVs.\n\nWhat medical problems do participants have when undergoing EVL or taking carvedilol? Researchers will compare the efficacy and safety of EVL to carvedilol for the prevention of first EVB in patients with HCC.\n\nParticipants will:\n\nUndergo EVL every 3-4 weeks until variceal eradication and then receive regular endoscopic follow-up according to the protocol, or Take carvedilol every day (start from 6.25 mg\u002Fd and then titrate to 12.5 mg\u002Fd if tolerable).\n\nVisit the clinic once every 2-3 months for checkups and tests. Keep a diary of their vital signs (SBP, DBP, and HR) as well as symptoms.",[263,31],"Hepatocellular Carcinoma (HCC)",[40,265,266,35],"Hepatocellular carcinoma","Nonselective beta-blocker","2025-02-11",{"date":269,"type":46},"2025-02-13",{"date":271,"type":46},"2024-10-01",{"date":273,"type":22},"2030-10",{"name":275,"class":276},"Taipei Veterans General Hospital, Taiwan","OTHER_GOV",{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":283,"eligibilityCriteria":284,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":256,"enrollmentInfo":285,"targetDuration":4,"studyType":23,"phases":287,"briefSummary":288,"conditions":289,"keywords":290,"overallStatus":140,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":296,"locationsCount":150},"100561793","phase-4-carvedilol-plus-evl-or-not-for-the-primary-prevention-of-esophageal-variceal-bleeding-in-carvedilol-non-responders-100561793","NCT06594783","Carvedilol Plus EVL or Not for the Primary Prevention of Esophageal Variceal Bleeding in Carvedilol Non-responders","Carvedilol Plus Endoscopic Ligation or Not for the Primary Prevention of Esophageal Variceal Bleeding in Carvedilol Non-responders: a Randomized Controlled Trial","CVL-NR","Inclusion Criteria:\n\n\\- Cirrhotic patients with esophageal varices who, after carvedilol treatment, continue to experience variceal enlargement or develop new red color signs.\n\nExclusion Criteria:\n\n* Age under 18 or over 90 years.\n* History of esophageal variceal bleeding.\n* Previous treatment for esophageal varices, including endoscopic variceal ligation, endoscopic sclerotherapy, transjugular intrahepatic portosystemic shunt, or surgery.\n* Contraindications to non-selective beta-blockers, including severe atrioventricular block, chronic obstructive pulmonary disease (COPD), asthma, uncontrolled diabetes mellitus, or severe peripheral artery disease.\n* Presence of end-stage organ diseases, including hepatocellular carcinoma or other terminal cancers, heart failure, or renal failure.\n* Pregnant women.\n* Refusal to participate in the study.",{"count":286,"type":22},80,[260],"The goal of this clinical trial is to evaluate whether carvedilol plus endoscopic variceal ligation (EVL) is more effective for the primary prevention of esophageal variceal bleeding than carvedilol alone in carvedilol non-responders. It will also learn about the safety of carvedilol combined with EVL in patients with cirrhosis.\n\nThe main questions it aims to answer are:\n\nWhether carvedilol plus EVL is more effective than carvedilol alone in preventing the first esophageal variceal bleeding in cirrhotic patients unresponsive to carvedilol.\n\nWhat medical problems do participants have when taking carvedilol or taking carvedilol combined with undergoing EVL? Researchers will compare the efficacy and safety of carvedilol with or without EVL in preventing the first esophageal variceal bleeding in cirrhotic patients unresponsive to carvedilol.\n\nParticipants will:\n\nTake carvedilol every day (start from 6.25 mg\u002Fd and then titrate to 12.5 mg\u002Fd if tolerable) and undergo EVL every 3-4 weeks until variceal eradication followed by regular endoscopic follow-up according to the protocol, or Take carvedilol alone every day (start from 6.25 mg\u002Fd and then titrate to 12.5 mg\u002Fd if tolerable).\n\nVisit the clinic once every 2-3 months for checkups and tests. Keep a diary of their vital signs (SBP, DBP, and HR) as well as symptoms.",[34,31],[34,40,266,35],"2025-02-10",{"date":267,"type":46},{"date":294,"type":46},"2025-01-06",{"date":273,"type":22},{"name":275,"class":276},{"id":298,"slug":299,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":4,"eligibilityCriteria":303,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":304,"targetDuration":4,"studyType":23,"phases":306,"briefSummary":309,"conditions":310,"keywords":4,"overallStatus":140,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":150},"100400873","phase-2-carvedilol-versus-endoscopic-band-ligation-for-primary-prophylaxis-of-oesophageal-variceal-bleeding-100400873","NCT04499898","Carvedilol Versus Endoscopic Band Ligation for Primary Prophylaxis of Oesophageal Variceal Bleeding","Randomized Controlled Trial of Carvedilol Versus Endoscopic Band Ligation for Primary Prophylaxis of Oesophageal Variceal Bleeding in Cirrhotic Patients With Arterial Hypertension","Inclusion Criteria:\n\n* • Aged \\>18 years\n\n  * Cirrhotic patients with arterial hypertension\n  * Endoscopic evidence of medium\u002Flarge-sized esophageal varices\n\nExclusion Criteria:\n\n* • History of variceal bleeding or previous primary prevention of varices.\n\n  * Portal vein thrombosis or previous porto-systemic shunts as TIPS.\n  * Patients on drugs affecting portal pressure (beta blockers, nitrates).\n  * Advanced cardiovascular disease including acute myocardial infarction, atrio-ventricular block, congestive heart failure, chronic peripheral ischemia, severe bradycardia.\n  * Patients with severe respiratory diseases (COPD, bronchial asthma).\n  * Uncontrolled diabetes mellitus\n  * Renal impairment\n  * Hepatocellular carcinoma\n  * Allergy to carvedilol\n  * Pregnancy or lactation",{"count":305,"type":22},306,[307,308],"PHASE2","PHASE3","Carvedilol versus endoscopic band ligation for primary prophylaxis of oesophageal variceal bleeding in cirrhotic patients with arterial hypertension",[31],"2020-08-01",{"date":313,"type":46},"2020-08-05",{"date":315,"type":46},"2018-10-01",{"date":317,"type":22},"2030-12-10",{"name":319,"class":53},"Sherief Abd-Elsalam"]